Original paper
PMH42 - COST-UTILITY ANALYSIS OF CARIPRAZINE COMPARED TO RISPERIDONE AMONG PATIENTS WITH NEGATIVE SYMPTOMS OF SCHIZOPHRENIA IN SELECTED NORDIC COUNTRIES
Abstract
Currently, negative symptoms are regarded as a core aspect of schizophrenia and considered the major contributor to low function levels and deterioration in most patients with schizophrenia. Cariprazine is the first drug enabling psychiatrists to optimally treat schizophrenia patients with negative symptoms. The main objective of this research was to assess the cost-effectiveness of cariprazine compared to risperidone, in the treatment of...
Paper Details
Title
PMH42 - COST-UTILITY ANALYSIS OF CARIPRAZINE COMPARED TO RISPERIDONE AMONG PATIENTS WITH NEGATIVE SYMPTOMS OF SCHIZOPHRENIA IN SELECTED NORDIC COUNTRIES
Published Date
Oct 1, 2018
Journal
Volume
21
Pages
S281 - S281
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History